"200mg daily DHA for infants," new guidelines

3 March 2008

New recommendations published in the January 2008 issue of the Journal of Perinatal Medicine recommend that the fetus and neonate should receive long-chain polyunsaturated fatty acids (LC-PUFA) in amounts sufficient to support optimal visual and cognitive development. Moreover, the consumption of oils rich in omega-3 LC-PUFA during pregnancy reduces the risk for early premature birth.

The guidelines, which are supported by the World Association of Perinatal Medicine and the Child Health Foundation, suggest that pregnant and lactating women should aim for an average daily intake of at least 200mg docosahexaenoic acid. For healthy-term infants, the authors recommend and fully endorse breastfeeding, which supplies preformed LC-PUFA, as the preferred method. When this is not possible, they advise the use of an infant formula with DHA at levels between 0.2 and 0.5 weight percent of total fat and the minimum amount of arachidonic acid.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight